TRIM68 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q6AZZ1 |
---|---|
Clone Names | 100408353 |
Gene ID | 55128 |
---|---|
Other Names | E3 ubiquitin-protein ligase TRIM68, 632-, RING finger protein 137, SSA protein SS-56, SS-56, Tripartite motif-containing protein 68, TRIM68, GC109, RNF137, SS56 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | TRIM68 |
---|---|
Synonyms | GC109, RNF137, SS56 |
Function | Functions as a ubiquitin E3 ligase. Acts as a coactivator of androgen receptor (AR) depending on its ubiquitin ligase activity. |
Cellular Location | Cytoplasm, perinuclear region. Nucleus. Note=Colocalized with AR in nucleus |
Tissue Location | Widely expressed. Expressed at high levels in prostate cancer cell lines. Up-regulation could be restricted to androgen-dependent cells. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene contains a RING fingerdomain, a motif present in a variety of functionally distinctproteins and known to be involved in protein-protein andprotein-DNA interactions. This gene is expressed in many cancercell lines. Its expression in normal tissues, however, was found tobe restricted to prostate. This gene was also found to bedifferentially expressed in androgen-dependent versusandrogen-independent prostate cancer cells.
References
Malhotra, A., et al. Diabetes Metab. Res. Rev. 25(8):740-747(2009)Miyajima, N., et al. Cancer Res. 68(9):3486-3494(2008)Chang, G.T., et al. Eur. J. Cancer 37(16):2129-2134(2001)Billaut-Mulot, O., et al. J. Clin. Invest. 108(6):861-869(2001)Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.